Glenmark Pharma Q1 Review - Steady Traction Exhibited In Domestic Formulation, Rest Of World: Motilal Oswal


BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Glenmark Pharmaceuticals Ltd. delivered better-than-expected Q1 FY23 result fueled by better operating margin. While the domestic formulation (excluding Covid basis) and rest of world markets grew strongly, the U.S. segment saw steep YoY decline.

We tweak our earnings per share estimates of Glenmark Pharma by up 6%/up 3% for FY23/FY24, respectively, to factor in robust performance in consumer care business, better outlook in ROW markets and improved operating leverage.

We expect 12% earnings compound annual growth rate over FY22-24, led by 4% sales CAGR and 100 basis points margin expansion because of:

  1. better-than-industry growth in domestic formulation,

  2. portfolio expansion and

  3. capturing newer markets in the Europe region

Click on the attachment to read the full report:


This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.


Image and article originally from Read the original article here.